lAfter
‘A” Performance Gains Difficult to Attain.
nExamples:
–Diminishing
R&D in Pharmaceuticals
lRise
of “me too” Drugs & Increased Price Competition
lProzac
(Lily), Zoloft (Pfizer), Praxil (SKB)
–Limits to Line
Width Reduction in Semiconductors
lPhoto-lithography
facing Diminishing Returns
lCan
we go below 0.1 microns?
–Rising
R&D Costs in Microprocessors
l386
$100m, 486 $1 billion, Pentium, $5 billion
lLine
width in semiconductors
lProbability
of Paradigm Shift Increases